Company intelligence / Profile preview
Aptahem
Malmö, Swedenaptahem.com ↗
- Ownership
- Private
- Employees
- ~4
- Development stage
- Other
01
Overview
Aptahem is a clinical-stage Swedish biotech company developing aptamer-based therapeutics for acute life-threatening conditions, primarily sepsis. Its lead candidate, APTA‑1, has advanced to Phase 1 clinical trials. The company collaborates with academic institutions and is expanding its pipeline to other inflammatory indications.
- Therapeutic areas
- ImmunologyInfectious Diseases
- Modalities
- AptamerRNA therapy
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Örebro UniversitySeattle Children’s Research InstituteUniversity Health NetworkHongene Biotech
Beyond the preview
Go deeper on Aptahem.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aptahem.